Cognition Therapeutics up on more NIH grant for Alzheimer's drug trial

Cognition Therapeutics

27/09/2022 13:52

** Shares of drug developer Cognition Therapeutics  CGTX.O 
rise 9.9% to $1.88 in premarket trading 
    ** Co recieves $2.14 mln grant from National Institutes of
Health (NIH) to complete an ongoing trial of its experimental
Alzheimer's disease treatment
    ** NIH had granted CGTX $3.2 mln in 2020 for the study
    ** Study, which is enrolling 16 adults with mild-to-moderate
Alzheimer's disease, aims to assess safety, tolerability and
efficacy of CT1812 and its impact on electrical activity in
brain
    ** Stock has lost about 73% YTD as of last close
 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com;))